These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35863362)

  • 1. Advancing the prevention and treatment of HIV in children: priorities for research and development.
    Penazzato M; Townsend CL; Sam-Agudu NA; Ruel TD; Archary M; Bekker A; Cressey TR; Colbers A; Sugandhi N; Rojo P; Rakhmanina N; Watkins M; Frigati L; Mukui I; Hafiz A; Vicari M; Capparelli EV; Abrams EJ;
    Lancet HIV; 2022 Sep; 9(9):e658-e666. PubMed ID: 35863362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.
    Penazzato M; Townsend CL; Rakhmanina N; Cheng Y; Archary M; Cressey TR; Kim MH; Musiime V; Turkova A; Ruel TD; Rabie H; Sugandhi N; Rojo P; Doherty M; Abrams EJ;
    Lancet HIV; 2019 Sep; 6(9):e623-e631. PubMed ID: 31498110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents.
    Abrams EJ; Capparelli E; Ruel T; Mirochnick M
    Clin Infect Dis; 2022 Nov; 75(Suppl 4):S562-S570. PubMed ID: 36410381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.
    Penazzato M; Lewis L; Watkins M; Prabhu V; Pascual F; Auton M; Kreft W; Morin S; Vicari M; Lee J; Jamieson D; Siberry GK
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.
    Nachman S; Townsend CL; Abrams EJ; Archary M; Capparelli E; Clayden P; Lockman S; Jean-Philippe P; Mayer K; Mirochnick M; McKenzie-White J; Struble K; Watts H; Flexner C
    Lancet HIV; 2019 Aug; 6(8):e552-e558. PubMed ID: 31307946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies.
    Jacobs TG; Schouwenburg S; Penazzato M; Archary M; Ruel TD; van den Anker J; Burger DM; Cressey TR; Abrams EJ; Lyall H; Bekker A; Colbers A; ;
    Lancet HIV; 2022 Sep; 9(9):e649-e657. PubMed ID: 35863363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action.
    Penazzato M; Watkins M; Morin S; Lewis L; Pascual F; Vicari M; Lee J; Hargreaves S; Doherty M; Siberry GK
    Lancet HIV; 2018 May; 5(5):e259-e264. PubMed ID: 29739700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Global Research Agenda for Adolescents Living With HIV.
    Armstrong A; Nagata JM; Vicari M; Irvine C; Cluver L; Sohn AH; Ferguson J; Caswell G; Njenga LW; Oliveras C; Ross D; Puthanakit T; Baggaley R; Penazzato M
    J Acquir Immune Defic Syndr; 2018 Aug; 78 Suppl 1(1):S16-S21. PubMed ID: 29994915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Global Research Agenda for Pediatric HIV.
    Penazzato M; Irvine C; Vicari M; Essajee SM; Sharma A; Puthanakit T; Abrams EJ; Doherty M
    J Acquir Immune Defic Syndr; 2018 Aug; 78 Suppl 1(1):S10-S15. PubMed ID: 29994914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
    Mofenson LM; Brady MT; Danner SP; Dominguez KL; Hazra R; Handelsman E; Havens P; Nesheim S; Read JS; Serchuck L; Van Dyke R; ; ; ; ;
    MMWR Recomm Rep; 2009 Sep; 58(RR-11):1-166. PubMed ID: 19730409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antiretroviral resistance in children with HIV in low- and middle-income countries.
    Fitzgerald F; Penazzato M; Gibb D
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S85-92. PubMed ID: 23687294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.
    Saag MS; Gandhi RT; Hoy JF; Landovitz RJ; Thompson MA; Sax PE; Smith DM; Benson CA; Buchbinder SP; Del Rio C; Eron JJ; Fätkenheuer G; Günthard HF; Molina JM; Jacobsen DM; Volberding PA
    JAMA; 2020 Oct; 324(16):1651-1669. PubMed ID: 33052386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action.
    Penazzato M; Lockman S; Colbers A; Renaud F; Calmy A; Clayden P; Vicari M; Mahaka IC; Zech JM; Irvine C; Abrams EJ;
    J Int AIDS Soc; 2022 Jul; 25 Suppl 2(Suppl 2):e25912. PubMed ID: 35851834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Priorities for the Intersection of Alcohol and HIV/AIDS in Low and Middle Income Countries: A Priority Setting Exercise.
    Gordon S; Rotheram-Borus MJ; Skeen S; Parry C; Bryant K; Tomlinson M
    AIDS Behav; 2017 Nov; 21(Suppl 2):262-273. PubMed ID: 28975440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating future trends in paediatric HIV.
    Penazzato M; Bendaud V; Nelson L; Stover J; Mahy M
    AIDS; 2014 Nov; 28 Suppl 4(4):S445-51. PubMed ID: 25409099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine viral load monitoring in HIV-infected infants and children in low- and middle-income countries: challenges and opportunities.
    Arpadi SM; Shiau S; De Gusmao EP; Violari A
    J Int AIDS Soc; 2017 Nov; 20 Suppl 7(Suppl 7):. PubMed ID: 29171190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.